{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:05:23Z","timestamp":1776866723844,"version":"3.51.2"},"update-to":[{"DOI":"10.1002\/14651858.cd011403","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T00:00:00Z","timestamp":1525651200000}}],"reference-count":70,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011403.pub2","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T20:52:52Z","timestamp":1525726372000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment for hepatitis C virus-associated mixed cryoglobulinaemia"],"prefix":"10.1002","volume":"2018","author":[{"given":"Nuria","family":"Montero","sequence":"first","affiliation":[{"name":"Hospital Universitari de Bellvitge; Department of Nephrology; Feixa Illarga s\/n L'Hospitalet de Llobregat Barcelona Spain 08907"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Fav\u00e0","sequence":"additional","affiliation":[{"name":"Hospital Universitari de Bellvitge; Department of Nephrology; Feixa Illarga s\/n L'Hospitalet de Llobregat Barcelona Spain 08907"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Hospital del Mar-IMIM; Department of Nephrology; Passeig Maritim 25-29 Barcelona Barcelona Spain 08003"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Barrios","sequence":"additional","affiliation":[{"name":"Hospital del Mar-IMIM; Department of Nephrology; Passeig Maritim 25-29 Barcelona Barcelona Spain 08003"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep M","family":"Cruzado","sequence":"additional","affiliation":[{"name":"Hospital Universitari de Bellvitge; Department of Nephrology; Feixa Illarga s\/n L'Hospitalet de Llobregat Barcelona Spain 08907"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Pascual","sequence":"additional","affiliation":[{"name":"Hospital del Mar-IMIM; Department of Nephrology; Passeig Maritim 25-29 Barcelona Barcelona Spain 08003"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Soler","sequence":"additional","affiliation":[{"name":"Hospital del Mar-IMIM; Department of Nephrology; Passeig Maritim 25-29 Barcelona Barcelona Spain 08003"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,5,7]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD011403.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1182\/blood.V84.10.3336.3336","article-title":"Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study","volume":"84","author":"Dammacco","year":"1994","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD011403.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","article-title":"Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study","volume":"116","author":"Dammacco","year":"2010","journal-title":"Blood"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011403.pub2-BIB0003|cit3","first-page":"2201","article-title":"A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (RTX) monotherapy versus the best available treatment in patients with mixed cryoglobulinemia syndrome [abstract]","volume":"62","author":"Vita","year":"2010","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD011403.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"Vita","year":"2012","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011403.pub2-BIB0005|cit5","first-page":"93","article-title":"A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (RTX) monotherapy versus the best available treatment (BAT) in patients with mixed cryoglobulinemia syndrome [abstract no: OP0120]","volume":"69","author":"Vita","year":"2010","journal-title":"Annals of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD011403.pub2-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Quartuccio L Zuliani F Corazza L Scaini P Zani R Lenzi M Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study Journal of Autoimmunity 2015 88 93 26255249","DOI":"10.1016\/j.jaut.2015.07.012"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011403.pub2-BIB0007|cit7","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2014-eular.3872","article-title":"Rituximab monotherapy of severe HCV-related cryoglobulinemic vasculitis for more than 2 years: Follow-up of a randomized controlled multicentre study [abstract]","volume":"73","author":"Quartuccio","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011403.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1136\/gut.34.2_Suppl.S144","article-title":"Interferon alfa-2b in mixed cryoglobulinaemia: a controlled crossover trial","volume":"34","author":"Ferri","year":"1993","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011403.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/0277-5379(91)90583-Y","article-title":"Alpha interferon in the treatment of mixed cryoglobulinaemia patients","volume":"27 Suppl 4","author":"Ferri","year":"1991","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD011403.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood.V81.5.1132.1132","article-title":"Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial","volume":"81","author":"Ferri","year":"1993","journal-title":"Blood"},{"issue":"2 Pt II","key":"10.1002\/14651858.CD011403.pub2-BIB0011|cit11","first-page":"66","article-title":"Effects of alpha-interferon on clinico-serological parameters of mixed cryoglobulinemia [abstract]","volume":"21","author":"Ferri","year":"1991","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1002\/14651858.CD011403.pub2-BIB0012|cit12","first-page":"S181","article-title":"Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia","volume":"13 Suppl 13","author":"Mazzaro","year":"1995","journal-title":"Clinical & Experimental Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD011403.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S1590-8658(00)80335-7","article-title":"Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis","volume":"32","author":"Mazzaro","year":"2000","journal-title":"Digestive & Liver Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011403.pub2-BIB0014|cit14","first-page":"233","article-title":"Interferon alfa VS steroids in patients with HCV cryoglobulinemic glomerulonephritis [abstract]","volume":"30","author":"Mazzaro","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD011403.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1056\/NEJM199403173301104","article-title":"Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus","volume":"330","author":"Misiani","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011403.pub2-BIB0016|cit16","first-page":"S187","article-title":"GISC protocol experience in the treatment of essential mixed cryoglobulinaemia","volume":"13 Suppl 13","author":"Pioltelli","year":"1995","journal-title":"Clinical & Experimental Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD011403.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.34322","article-title":"A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis","volume":"64","author":"Sneller","year":"2012","journal-title":"Arthritis & Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD011403.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jca.20222","article-title":"Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemia","volume":"24","author":"Stefanutti","year":"2009","journal-title":"Journal of Clinical Apheresis"},{"issue":"9","key":"10.1002\/14651858.CD011403.pub2-BIB0019|cit19","first-page":"839","article-title":"Double-blind study on the antiproteinuric effect of captopril versus placebo in cryoglobulinaemic glomerulonephritis: a Franco-Hispano-Italian study","volume":"4","author":"Anonymous","year":"1989","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD011403.pub2-BIB0020|cit20","first-page":"509","article-title":"Fish-oil fatty acid supplementation in mixed cryoglobulinemia: a preliminary report","volume":"12","author":"Candela","year":"1994","journal-title":"Clinical & Experimental Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD011403.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0002-9343(89)80607-2","article-title":"Low-antigen-content diet in the treatment of patients with mixed cryoglobulinemia","volume":"87","author":"Ferri","year":"1989","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011403.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF02990568","article-title":"Long-term results regarding the interferon alpha-2b in the treatment essential cryoglobulinemia","volume":"12","author":"Lauta","year":"1995","journal-title":"Medical Oncology"},{"issue":"2-4","key":"10.1002\/14651858.CD011403.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000236270","article-title":"Deflazacort versus prednisone in the treatment of essential mixed cryoglobulinemia: a between-patient controlled clinical study","volume":"99","author":"Vacca","year":"1992","journal-title":"International Archives of Allergy & Immunology"},{"issue":"10","key":"10.1002\/14651858.CD011403.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","article-title":"Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients","volume":"41","author":"Bartolucci","year":"2002","journal-title":"Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD011403.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/annrheumdis-2013-203883","article-title":"Hepatitis C virus-induced vasculitis: therapeutic options","volume":"73","author":"Cacoub","year":"2014","journal-title":"Annals of the rheumatic diseases"},{"issue":"9","key":"10.1002\/14651858.CD011403.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.amjmed.2015.02.017","article-title":"Cryoglobulinemia vasculitis","volume":"128","author":"Cacoub","year":"2015","journal-title":"American Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011403.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/liv.13465","article-title":"Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: from interferon-based to direct-acting antivirals era","volume":"37","author":"Cacoub","year":"2017","journal-title":"Liver International"},{"key":"10.1002\/14651858.CD011403.pub2-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Chandesris MO Gayet S Schleinitz N Doudier B Harle JR Kaplanski G Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinaemia Rheumatology 2004 532 3 15024144","DOI":"10.1093\/rheumatology\/keh080"},{"issue":"8","key":"10.1002\/14651858.CD011403.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/ki.2009.247","article-title":"Hepatitis C virus-induced cryoglobulinemia","volume":"76","author":"Charles","year":"2009","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD011403.pub2-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Cohen C Mekinian A Saidenberg-Kermanac'h N Stirnemann J Fenaux P Gherardi R Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis Annals of the Rheumatic Diseases 2012 628 9 22121135","DOI":"10.1136\/annrheumdis-2011-200501"},{"issue":"4","key":"10.1002\/14651858.CD011403.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/00325481.2015.1021660","article-title":"Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: a case series","volume":"127","author":"Cornella","year":"2015","journal-title":"Postgraduate Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011403.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2000-9613","article-title":"The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy","volume":"20","author":"Dammacco","year":"2000","journal-title":"Seminars in Liver Disease"},{"issue":"11","key":"10.1002\/14651858.CD011403.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1056\/NEJMra1208642","article-title":"Therapy for hepatitis C virus-related cryoglobulinemic vasculitis","volume":"369","author":"Dammacco","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011403.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10238-016-0410-9","article-title":"The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review","volume":"16","author":"Dammacco","year":"2016","journal-title":"Clinical & Experimental Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011403.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/BOR.0000000000000390","article-title":"Cryoglobulinemia vasculitis: how to handle","volume":"29","author":"Desbois","year":"2017","journal-title":"Current Opinion in Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD011403.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"55","author":"European Association for Study of Liver","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD011403.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.semarthrit.2003.10.001","article-title":"Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients","volume":"33","author":"Ferri","year":"2004","journal-title":"Seminars in Arthritis & Rheumatism"},{"issue":"7650","key":"10.1002\/14651858.CD011403.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD011403.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.28753","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia","volume":"64","author":"Gragnani","year":"2016","journal-title":"Hepatology"},{"issue":"7414","key":"10.1002\/14651858.CD011403.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011403.pub2-BIB0041|cit41","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"9","key":"10.1002\/14651858.CD011403.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/ard.2007.083584","article-title":"Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients","volume":"67","author":"Josselin","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD011403.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/BOR.0b013e3283368099","article-title":"Interferon therapy in rheumatic diseases: state-of-the-art 2010","volume":"22","author":"Kotter","year":"2010","journal-title":"Current Opinion in Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD011403.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2016.12.019","article-title":"Increased peripheral CD4+ regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C","volume":"66","author":"Langhans","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD011403.pub2-BIB0045|cit45","first-page":"434","article-title":"Hepatitis C virus and its renal manifestations: a review and update","volume":"8","author":"Latt","year":"2012","journal-title":"Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD011403.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"502156","DOI":"10.1155\/2012\/502156","article-title":"Hepatitis C virus infection and mixed cryoglobulinemia","volume":"2012","author":"Lauletta","year":"2012","journal-title":"Clinical & Developmental Immunology"},{"issue":"20","key":"10.1002\/14651858.CD011403.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMra1213651","article-title":"Current and future therapies for hepatitis C virus infection","volume":"368","author":"Liang","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011403.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011403.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"e55285","DOI":"10.1371\/journal.pone.0055285","article-title":"Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting","volume":"8","author":"Maasoumy","year":"2013","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"8","key":"10.1002\/14651858.CD011403.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/ajg.2017.199","article-title":"Editorial: Benefit of direct-acting antiviral therapy for cryoglobulinemia due to hepatitis C infection","volume":"112","author":"Martin","year":"2017","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD011403.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/MD.0b013e3181c1750f","article-title":"Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection","volume":"88","author":"Matignon","year":"2009","journal-title":"Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011403.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1155\/2012\/947676","article-title":"An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver","volume":"26","author":"Myers","year":"2012","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD011403.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.autrev.2011.01.008","article-title":"Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients","volume":"10","author":"Pietrogrande","year":"2011","journal-title":"Autoimmunity Reviews"},{"issue":"9813","key":"10.1002\/14651858.CD011403.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0140-6736(11)60242-0","article-title":"The cryoglobulinaemias","volume":"379","author":"Ramos-Casals","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD011403.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/jca.20166","article-title":"Double-filtration plasmapheresis in the treatment of leg ulcers in cryoglobulinemia","volume":"23","author":"Ramunni","year":"2008","journal-title":"Journal of Clinical Apheresis"},{"issue":"1","key":"10.1002\/14651858.CD011403.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/BOR.0b013e3282f1330c","article-title":"Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis","volume":"20","author":"Saadoun","year":"2008","journal-title":"Current Opinion in Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD011403.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2012-202770","article-title":"Peg-IFNalpha\/ribavirin\/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24","volume":"73","author":"Saadoun","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD011403.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2015-208339","article-title":"Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study","volume":"75","author":"Saadoun","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD011403.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1473-3099(05)70053-0","article-title":"Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations","volume":"5","author":"Sansonno","year":"2005","journal-title":"Lancet Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD011403.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/rheumatology\/kel425","article-title":"Hepatitis C virus infection, cryoglobulinaemia, and beyond","volume":"46","author":"Sansonno","year":"2007","journal-title":"Rheumatology"},{"issue":"0","key":"10.1002\/14651858.CD011403.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/jvh.12746","article-title":"Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents","volume":"24","author":"Schiavinato","year":"2017","journal-title":"Journal of Viral Hepatitis"},{"issue":"3","key":"10.1002\/14651858.CD011403.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jca.21276","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue","volume":"28","author":"Schwartz","year":"2013","journal-title":"Journal of Clinical Apheresis"},{"key":"10.1002\/14651858.CD011403.pub2-BIB0063|cit63","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD011403.pub2-BIB0064|cit64","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"3","key":"10.1002\/14651858.CD011403.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"M315","DOI":"10.1097\/00002480-199507000-00021","article-title":"Cryofiltration apheresis for treatment of cryoglobulinemia associated with hepatitis C","volume":"41","author":"Siami","year":"1995","journal-title":"ASAIO Journal"},{"issue":"2","key":"10.1002\/14651858.CD011403.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents","volume":"63","author":"Sise","year":"2016","journal-title":"Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD011403.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"e0145953","DOI":"10.1371\/journal.pone.0145953","article-title":"Efficacy of second generation direct-acting antiviral agents for treatment naive hepatitis C genotype 1: a systematic review and network meta-analysis","volume":"10","author":"Suwanthawornkul","year":"2015","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"1","key":"10.1002\/14651858.CD011403.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/BOR.0b013e32835b15f7","article-title":"Cryoglobulinemia vasculitis: an update","volume":"25","author":"Terrier","year":"2013","journal-title":"Current Opinion in Rheumatology"},{"key":"10.1002\/14651858.CD011403.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Medical Research Methodology"},{"issue":"11","key":"10.1002\/14651858.CD011403.pub2-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011403","article-title":"Treatment for hepatitis C virus-associated cryoglobulinaemic vasculitis","author":"Montero","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011403.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T06:34:21Z","timestamp":1668062061000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011403.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,5,7]]},"references-count":70,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011403.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,7]]}}}